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D-Alanine:D-alanine ligase (EC 6.3.2.4; Ddl) catalyzes the ATP-driven ligation of two D-alanine (D-Ala)
molecules to form the D-alanyl:D-alanine dipeptide. This molecule is a key building block in peptidoglycan
biosynthesis, making Ddl an attractive target for drug development. D-Cycloserine (DCS), an analog of
D-Ala and a prototype Ddl inhibitor, has shown promise for the treatment of tuberculosis. Here, we report
the crystal structure of Mycobacterium tuberculosis Ddl at a resolution of 2.1 Å. This structure indicates
that Ddl is a dimer and consists of three discrete domains; the ligand binding cavity is at the intersection
of all three domains and conjoined by several loop regions. The M. tuberculosis apo Ddl structure shows
a novel conformation that has not yet been observed in Ddl enzymes from other species. The nucleotide
and D-alanine binding pockets are flexible, requiring significant structural rearrangement of the bordering
regions for entry and binding of both ATP and D-Ala molecules. Solution affinity and kinetic studies
showed that DCS interacts with Ddl in a manner similar to that observed for D-Ala. Each ligand binds to
two binding sites that have significant differences in affinity, with the first binding site exhibiting high
affinity. DCS inhibits the enzyme, with a 50% inhibitory concentration (IC50) of 0.37 mM under standard
assay conditions, implicating a preferential and weak inhibition at the second, lower-affinity binding site.
Moreover, DCS binding is tighter at higher ATP concentrations. The crystal structure illustrates potential
drugable sites that may result in the development of more-effective Ddl inhibitors.
Tuberculosis (TB), caused by Mycobacterium tuberculosis,
remains a leading factor in worldwide morbidity and mor-
tality. Recent trends indicate that TB cases due to multi-
drug-resistant (MDR) M. tuberculosis and extensively drug-
resistant (XDR) M. tuberculosis are continuously increasing,
with estimates that at least 490,000 cases of MDR M. tuber-
culosis infections occur each year (16). Current therapies
not only are ineffective against MDR and XDR M. tubercu-
losis but also require long treatment courses (16). Unfortu-
nately, new anti-TB drugs are not being developed at a
suitable rate to keep pace with the rising spread of drug-
resistant M. tuberculosis. Thus, there is an urgent need for
timely development of novel anti-TB compounds to effec-
tively treat drug-resistant cases and shorten treatment pro-
tocols.
The pathways involved in bacterial cell wall biosynthesis are
key targets for novel antibiotic design (35). The M. tuberculosis
cell wall is a lipid rich structure with a rigid peptidoglycan
backbone (2). Peptidoglycan is a branched polymer consisting
of -(1,4)-linked N-acetyl- or N-glycolyl-muramic acid and N-
acetyl-glucosamine moieties (27, 42). Small peptide chains
consisting of D-alanine (D-Ala), D-glutamate, and meso-diamin-
opimelate extend from the N-glycolyl or N-acetylmuramic acid
component and cross-link adjacent N-glycolyl/acetylmuramic
chains via peptide bridges (17). The peptidoglycan backbone
confers the cell wall tensile strength; thus, inhibiting this cross-
linking leads to extensively weaker cell walls and cell death.
D-Ala plays a key role in peptidoglycan cross-linking (31, 37).
Therefore, enzymes involved in the D-Ala pathway of pepti-
doglycan biosynthesis are attractive targets for novel antibiotic
design.
D-Alanine:D-alanine ligase, also denoted D-alanyl:D-alanine (D-
Ala:D-Ala) synthetase, Ddl, and EC 6.3.2.4, catalyzes the reaction
2 D-alanine  ATPO¡
Mg2
D-Ala:D-Ala  ADP  Pi.
Ddl enzymes from various microbial sources have multi-
ple ligand binding sites relevant to their catalytic activity:
D-Ala1 binds the first monomer of D-Ala with high affinity,
and D-Ala2 binds the second D-Ala with lower affinity (13,
39). In addition, there is a distinct ATP binding site (13).
The proposed mechanism for the reaction involves binding
of D-Ala to the D-Ala1 site, phosphorylation of the amino
acid’s carboxylate by the -phosphate of ATP, and subse-
quent binding to the D-Ala2 site. Ligation is completed upon
the nucleophilic attack of the amine at the D-Ala2 site on the
phosphorylated D-Ala at the D-Ala1 site to yield D-Ala:D-Ala
(13, 39). Inhibitors mimicking D-Ala or D-Ala:D-Ala have
been discovered, including D-cycloserine (DCS), cis- and
trans-DL-cyclothreonine, and compounds related to reaction
transition state intermediates, such as phosphinate and
phosphonate derivatives (32, 34).
DCS has been used as an anti-TB agent and is the only
Ddl inhibitor currently used in the treatment of bacterial
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infections (46). DCS inhibits Ddl by competitive inhibition,
but the relative contribution of each D-Ala site to this pro-
cess remains unknown (19, 31, 32, 40). DCS also inhibits
D-alanine racemase, the enzyme in the D-Ala synthesis path-
way that catalyzes the interconversion of L-Ala and D-Ala.
D-Alanine racemase provides a substrate to Ddl, and its
overexpression in Mycobacterium smegmatis leads to resis-
tance by target overproduction (4). It is unclear whether
D-alanine racemase, Ddl, or both are the target(s) of DCS
bactericidal action in M. tuberculosis. There are side effects
to DCS treatment, largely due to lack of specificity, which
have led to its limited use (46). Structure-based drug design
using DCS as a scaffold could aid in developing Ddl inhib-
itors with greater specificity and attenuated severity of side
effects. Unfortunately, no atomic level structural informa-
tion regarding M. tuberculosis Ddl has been reported, al-
though Ddl structures from other organisms are available
(13, 23, 25, 45).
To gain insights into the mechanism of action of DCS in
M. tuberculosis, we have solved the crystal structure of M.
tuberculosis Ddl to a 2.1-Å resolution. The overall structure
correlates with previously reported Ddl structures from
other microbial species. However, divergences in the pri-
mary and tertiary structures of M. tuberculosis Ddl, com-
pared to the levels for other organisms, show key differences
in the overall folding and active-site structure. We describe
the presence of novel pockets in the M. tuberculosis Ddl
structure and present fluorescence quenching binding affin-
ity studies, isothermal calorimetry titration data, and enzy-
matic assays. This combined analysis results in a more com-
plete picture of how M. tuberculosis Ddl interacts with ATP,
D-Ala, and DCS.
MATERIALS AND METHODS
Cloning, protein expression, and purification. M. tuberculosis H37Rv
genomic DNA was used as a template to PCR amplify the Ddl gene (Rv2981c
accession no. P95114), yielding a 1,122-nucleotide DNA fragment using prim-
ers 5-GCATATGAGTGCTAACGACCG-3 and 5-GCTAAGTGCCGATC
GCAAG-3. NdeI and HindIII were used to digest the fragment for subse-
quent ligation into the pET28b vector (Novagen) modified to contain an
N-terminal His tag followed by a tobacco etch virus (TEV) cleavage site for
removal of the His tag during protein purification. The Ddlb-pET28b vector
was transformed into BL21(DE3) Escherichia coli cells. For protein expres-
sion, a 10-ml starter culture was grown from a single colony overnight at 37°C.
The starter culture was used to inoculate a 1-liter culture. LB medium
supplemented with 30 g/ml kanamycin was used in all cell growths. Cells
were grown to an optical density of 0.5 and then induced with 0.5 mM
isopropyl 1-thio--D-galactopyranoside (IPTG). Ddl was expressed at 16°C
for 16 h. Cells were pelleted and stored at 80 to 120°C. Cells were
resuspended in buffer A (20 mM Tris-HCl [pH 8.0], 500 mM NaCl, 10 mM
imidazole [pH 8.0], and 2 mM -mercaptoethanol [BME]) and subjected to
two passes through a French press for lysis. Lysed cells were then clarified by
centrifugation at 15,000  g for 1 h. The supernatant was applied to a 5 ml
HisTrap crude His column (GE Healthcare), washed, and eluted with a
gradient of buffer B (20 mM Tris-HCl [pH 8.0], 500 mM NaCl, 500 mM
imidazole [pH 8.0], and 2 mM BME). Ddl was then dialyzed in 2 liters of
buffer A while being subjected to TEV proteolysis (at a ratio of 30:1 Ddl/TEV
by weight) for removal of the His tag. The cleaved protein was passed over
another HisTrap crude His column (GE Healthcare) equilibrated in buffer A
to remove uncleaved His-Ddl and His-tagged TEV protease. Ddl was dialyzed
to 20 mM Tris HCl (pH 8.0), 20 mM NaCl, and 2.0 mM dithiothreitol (DTT)
for storage. Purified protein was concentrated in a Centriprep 15-ml centrif-
ugal concentrator (Millipore) with a 30,000 molecular weight cutoff. The final
protein concentration was approximately 10 mg/ml.
Crystallization. Crystallization conditions were obtained by exploring sev-
eral commercially available sparse matrix screens, with hits arising almost
exclusively in the polyethylene glycol (PEG)/ion screen (Hampton Research).
Crystals for data collection were produced by mixing either a 1-l/1-l or a
1-l/1.5-l ratio of well solution to protein solution, with the well solution
(0.5 ml) consisting of 20% PEG 3350 and 0.2 M KNO3, using the vapor
diffusion method in a hanging-drop 24-well Limbro plate at 20°C. Crystals
grew to full size within 1 week (100 to 300 m on each side) and were of a
cubic shape.
Data collection, structure determination, and refinement. Crystals were
transferred to Paratone-N for cryoprotection and flash cooled to 100 K by
submersion into liquid nitrogen. All data collection was carried out at 100 K
at beamline 23ID at the Advanced Photon Source (Argonne National Lab-
oratory, Argonne, IL). Data were indexed, integrated, and scaled with the
HKL-2000 program in space group P21 to a resolution of 2.1 Å (33). The
phase problem was solved by molecular replacement using the program
Phaser (28). No homologues of Ddl (including E. coli, Staphylococcus aureus,
and Thermus thermophilus) yielded suitable cross-rotation or translation func-
tion solutions. With the use of the program Chainsaw, a homology model was
made using the S. aureus structure (Protein Data Bank [PDB] accession code
2i87) stripped of all water and ligands (25). A strong solution using the
homology model was then obtained in Phaser. The Phaser molecular replace-
ment solution was then refined in Phenix using simulated annealing at 5,000
K. The subsequent model was then subjected to multiple rounds of rebuilding
in Coot followed by B-factor and positional refinement in Phenix and CCP4
until R factors converged in the low 20s (1, 20). Stereochemistry was checked
by MolProbity, and the results are presented in Table 1, along with data
processing and refinement statistics (12).
Fluorescence quenching affinity experiments. The protein concentration was
3.0 M for all experiments in a total starting volume of 0.5 ml. Experiments
were carried out with 20 mM Tris-HCl (pH 8.0), 50 mM NaCl, 1 mM DTT.
TABLE 1. Data processing and refinement statistics
Parameter Value forapo Ddla
Data collection
Space group..................................................................P21
Cell dimensions
a, b, c (Å) .................................................................51.7, 108.3, 69.1
, ,  (°)..................................................................90.0, 99.9, 90.0
Resolution (Å) .............................................................20.0 (2.10)
Rmerge.............................................................................0.052 (0.406)
I /	I................................................................................24.6 (2.7)
Completeness (%) .......................................................93.9 (84.9)
Redundancy..................................................................3.6 (3.1)
Refinement
Resolution (Å) .............................................................20.0–2.1
No. of reflections .........................................................38,758
Rwork/Rfree .....................................................................17.34/22.10
No. of atoms
Protein.......................................................................4,557
Water.........................................................................383
B factors (Å2)
Protein.......................................................................44.7
Water.........................................................................47.7
Ramachandran statistics
Most favored ............................................................96.4%
Outliers .....................................................................0.3%
RMSDs
Bond lengths (Å) .....................................................0.004
Bond angles (°) ........................................................0.622
a Numbers in parentheses represent the highest-resolution shell.
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The DCS titrations were 0.5 l each and ranged from 1.0 nM to 10.0 mM.
D-Ala binding affinity was also determined in a similar manner, but assays
were performed from a range of 1.0 nM to 5.0 mM. ATP- and ATP-S-
saturated Ddl fluorescence quenching was achieved by bringing the Ddl
protein solution to 5.0 mM ATP and 1.0 mM MgCl2. Experiments using DCS
were buffered with 20 mM Tris-HCl (pH 7.0) to ensure that DCS was present
in a zwitterionic form shown to give maximum binding affinity with Ddl, as
demonstrated by previous studies (30). Fluorescence was achieved by excita-
tion at 295 nm, and the emission was measured at 338 nm. The data were fit
using GraphPadPrism5 (GraphPad Software, Inc.), using nonlinear regres-
sion.
Isothermal titration calorimetry. Because the inner filter effect of ATP could
not be overcome using intrinsic fluorescence quenching, the affinity of Ddl for
ATP was monitored using isothermal titration calorimetry (Microcal). Ddl
was thermostated at 30°C in the cell at a concentration of 40 M, ATP was
injected stepwise from a stock concentration of 400 M, and respective heat
changes were measured. Due to the large heat of hydration of ATP, ATP was
first injected into buffer and heat changes were subtracted from ATP injected
to the protein prior to analysis. Data were analyzed and fit by using Origin 5
software (MicroCal).
Ddl enzyme assay. Ddl endpoint assays by the thin-layer-chromatography
(TLC)-based method were carried out by a modified procedure as described
previously (15). Briefly, reaction mixtures were incubated at 37°C for various
times in the presence of 50 mM Tris-HCl (pH 7.8), 10 mM MgCl2, 10 mM
KCl, different concentrations of D-alanine and ATP, 2.5 mM glutathione, and
5.0 Ci [1-14C]D-alanine (100 Ci/ml; ICN Biochemicals, Inc., Costa Mesa,
CA) for radiometric assays. The Ddl enzyme at a final concentration of 10
g/ml was added to start the reactions. Assays were also run in the presence
of inhibitors added at appropriate concentrations, with adjustment of the pH
of the final solution to 7.8 as needed. For negative enzyme activity, controls
were inactivated by addition of SDS to give a final concentration of 0.25%.
Subsequently, 10 l of the reaction mixture was applied to cellulose-backed
TLC plates, and ascending chromatography was developed in n-butanol–
acetic acid–water (12:3:5) until the solvent reached the top of the plate. For
quantitative analysis, plates were directly dried at 100°C for 5 min and the
radioactivity corresponding to the position of D-Ala and D-Ala:D-Ala spots
was measured with a Bio-Rad Molecular Imager FX system (Bio-Rad). Al-
ternatively, Ddl activity was assayed by measuring the release of inorganic
phosphate (Pi), using the commercial continuous monitoring test for Pi re-
lease (EnzChek phosphate assay kit; Invitrogen).
Protein structure accession number. The atomic coordinates of Ddl have been
deposited in the Protein Data Bank under accession code 3LWB.
RESULTS
Ddl binding affinity for D-Ala, DCS, and ATP. We per-
formed assays to determine the binding affinities of DCS,
D-Ala, and ATP as well as a kinetic assay to determine the
inhibitory concentrations of DCS (Fig. 1; see also Fig. S1
and S2 in the supplemental material). Two binding sites for
DCS and one binding site for ATP per monomer were
assumed for the binding assays, as reported by previous
studies (44, 47):
DdlDCS17Ddl-DCS1DCS27Ddl-DCS1-DCS2 (1)
Ddl  ATP7 Ddl-ATP (2)
Intrinsic tryptophan fluorescence quenching was used to de-
termine the affinity of Ddl for D-Ala in the absence of ATP and
the affinity of nucleotide-bound Ddl for D-Ala. Ddl binding
events for D-Ala were a Kd1 of 95 nM and a, Kd2 of 1.2 mM,
where Kd1 and Kd2 are the dissociation constants at D-Ala sites
1 and 2, respectively (see Fig. S1A in the supplemental mate-
rial). Hence, ATP is not required for D-Ala binding, and ATP
binding may not be the first event in the overall reaction. To
further investigate the role of nucleotide binding in the affinity
of Ddl for D-Ala, we measured the binding affinity of ATP-S-
saturated Ddl for D-Ala (Fig. S1B). The nucleotide-bound en-
zyme showed, a Kd1 of 62 nM and a Kd2 of 0.97 mM. Nucleo-
tide binding is responsible for a decrease in the Kd1 value of 30
nM (i.e., corresponding to a 1.5-fold increase in affinity) and a
decrease of about 0.2 mM (i.e., corresponding to a 1.2-fold
increase in affinity) for the second binding event. Thus, D-Ala
affinity is not largely dependent on nucleotide binding.
Intrinsic tryptophan and tyrosine fluorescence quenching
was used to measure the binding affinity of Ddl in the absence
of ATP for DCS, which gave a Kd1 of 79 nM and a Kd2 of 0.99
mM (see Fig. S1C in the supplemental material), an almost
nonspecific binding event. Likewise, fluorescence quenching
gave a Kd1 value of ATP-S-saturated Ddl for DCS of 47 nM
(1.7-fold increase in affinity); the value for Kd2 was found to be
0.53 mM (1.9-fold increase in affinity) (Fig. S1D). Thus, the
effects of nucleotide binding are comparatively similar in both
DCS sites. When D-Ala and DCS binding were compared,
nucleotide binding was found to have a moderately greater
effect at the low-affinity site, making DCS a slightly better
inhibitor for the second binding event. To determine the af-
finity of apo Ddl for ATP, isothermal titration calorimetry was
carried out (Fig. S2). The affinity of apo M. tuberculosis Ddl for
ATP yielded a Kd of 14 
. The data were fit with one binding
event and showed no cooperativity across the dimer interface.
The affinity of ATP for M. tuberculosis Ddl is similar to the
values for similar Ddl enzymes from many other species, which
have affinities of 38 to 60 M (25, 47).
DCS inhibition of Ddl. To determine how the enzyme activ-
ity is inhibited by DCS, inhibition parameter values (50% in-
hibitory concentrations [IC50s]) were determined by kinetic
assays (Fig. 1A). An endpoint assay that monitors the progress
of the Ddl reaction by the formation of D-Ala:D-Ala as [14C]D-
Ala was provided as a substrate (15) was used first. Likewise,
the nonhydrolyzable substrate analog ,-methylene-adeno-
sine displayed approximately 60% inhibition as added in
equimolar amounts to ATP (i.e., both at 6.0 mM in the assay
mixture). Thus, inhibitors of both the D-Ala and the ATP
binding sites inhibited the Ddl reaction.
To obtain an IC50 for DCS inhibition, we used a continuous
assay that monitors the release of Pi as the result of ATP
hydrolysis in the presence of D-Ala (1.0 or 20 mM), ATP (0.5
or 6.0 mM), and various concentrations of DCS (Fig. 1B to E)
to determine an approximate inhibition value of 0.37 mM (Fig.
1B). This value is similar to the IC50 for E. coli DdlB at 0.32
mM (21). The value of the second binding event for DCS is
similar to that of the M. tuberculosis IC50 and published IC50s
for the E. coli Ddl (21, 45).
In general, IC50s are dependent upon the concentration(s)
of the substrate(s) {i.e., IC50  Ki [1  (substrate concentra-
tion/Km)] for simple competitive inhibition}. Thus, we deter-
mined the effect of varying D-Ala and ATP concentrations on
Ddl inhibition by DCS. Raising the D-Ala concentration 20-
fold (to 20 mM) while maintaining the ATP concentration at
6.0 mM resulted in competition, increasing the IC50 to 1.0 mM
(Fig. 1C). However, this value is less than the 10-fold effect
expected under the assumption of simple competitive inhibi-
tion (i.e., with a Ki approximately equal to the Kd2 for DCS and
a Km approximately equal to the Kd2 for D-Ala) (38). Thus, the
low-affinity site may significantly contribute to DCS inhibition.
Lowering the ATP concentration approximately 10-fold (to 0.5
mM) while maintaining D-Ala at 1.0 mM results in an increase
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of the IC50 for DCS to 0.8 mM (Fig. 1D). This is consistent
with the affinity data, but the effect at the kinetic level seems
more pronounced, reminiscent of potential heterotropic ligand
binding site interactions. The effect of ATP on the IC50 for
DCS is also observed at higher ATP concentrations (0.5 to 6.0
mM) than those predicted by the affinity data. Thus, the kinet-
ically relevant binding of ATP may occur at higher ATP con-
centrations. When both the D-Ala and the ATP concentrations
were varied together (to final values of 20 and 0.5 mM, respec-
tively), the IC50 increased to 2.5 mM (Fig. 1E), indicating that
DCS, under these conditions, cannot significantly inhibit Ddl.
Moreover, as observed at 6.0 mM ATP, the effect of a 20-fold
increase in the concentration of D-Ala had a minor effect on
the IC50, less than expected from classical competitive inhibi-
tion. The binding and kinetic parameter values are summa-
rized in Table 2.
FIG. 1. M. tuberculosis Ddl inhibition and binding assays. Inhibition assays were carried out with purified Ddl as described in Materials and
Methods. Enzyme activity was assayed by either the radiometric method (A) or the continuous Pi assay (B to E). IC50s were defined as the inhibitor
concentration that decreased the enzyme activity by 50% and were calculated using regression and graphic analyses, collecting data points (each
point represents the mean  the standard error of the mean [SEM]; n  3) obtained at specified inhibitor concentrations (A), spanning the range
from 1 nM DCS to 5 mM DCS (B), or observed in the linear range of the DCS dose-response curves (C to E).
TABLE 2. Kinetic, binding, and inhibition parameter values for the
M. tuberculosis Ddl enzyme
Parameter
(ligand) Value (mM) Conditions
a
Kd1 (D-Ala) 9.49  10
6 E
Kd1 (D-Ala) 6.15  10
6 E  (5 mM) ATP-S
Kd2 (D-Ala) 1.17 E
Kd2 (D-Ala) 9.70  10
1 E  (5 mM) ATP-S
Kd1 (DCS) 7.86  10
6 E
Kd1 (DCS) 4.71  10
6 E  (5 mM) ATP-S
Kd2 (DCS) 9.90  10
1 E
Kd2 (DCS) 5.30  10
1 E  (5 mM) ATP-S
Kd (ATP) 1.43  10
2 E
IC50 (DCS) 3.70  10
1 E  1.0 mM D-Ala  6.0 mM ATP
IC50 (DCS) 8.0  10
1 E  1.0 mM D-Ala  0.5 mM ATP
IC50 (DCS) 1.00 E  20.0 mM D-Ala  6.0 mM ATP
IC50 (DCS) 2.50 E  20 mM D-Ala  0.5 mM ATP
a E (Ddl enzyme) was used at 3 M for all fluorescence binding assays, 40 M
for the isothermal titration calorimetry, and 0.25 M (10 g/ml) in the kinetics
assays as described in Materials and Methods.
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Structure determination and overall structure. Ddl was
crystallized in the space group P21, with one dimer in the
asymmetric unit. The structure was solved by molecular re-
placement using diffraction data to a resolution of 2.1 Å. Crys-
tallographic data processing and refinement statistics are
shown in Table 1. Both subunits of the final model show high
structural similarity, with a core root mean square deviation
(RMSD) of 1.1 Å2.
Previous crystal structures of several species of Ddl have
revealed that it is a homodimer (13, 14, 25). The nucleotide
binding site and two D-Ala binding sites form a large cavity
spanning the centrally located boundaries of all three domains
in the protein. Conserved glutamate, glycine, and arginine res-
idues have been shown to comprise the first D-Ala binding site,
positioning D-Ala for nucleophilic attack on the -phosphate of
ATP, which forms a covalent phosphate–D-Ala intermediate.
The second D-Ala molecule is held in place by hydrogen bonds
from conserved serine and leucine residues as well as a con-
served tyrosine residue located on the  loop. The binding sites
position the D-Ala molecules in close proximity to each other,
allowing for covalent linkage.
Each Ddl monomer can be subdivided into three basic sub-
domains: an N-terminal domain (NTD) consisting of residues
from the N terminus extending to residue 140 comprising
-sheet regions 1 to 5 and -helices 1 to 3, a central domain
(MD) consisting of residues 141 to 232 encompassing -helices
4 to 7 and -sheet regions 6 to 10, and a C-terminal domain
(CTD) consisting of residues 233 to 373 and encompassing
-helices 8 to 11 and -sheet regions 11 to 17 (Fig. 2A). The
ATP catalytic cavity is centrally located within the protein and
is conjoined by the NTD, MD, and CTD and formed by H7,
B13, and H9, which comprise a loop region consisting of res-
idues 196 to 204, and a loop region consisting of amino acids 23
to 26 (Fig. 2B; see also Fig. S3 in the supplemental material).
The secondary and tertiary folds of the protein show high
similarity to those observed for other species, providing evi-
dence that the protein has been well conserved evolutionarily
among a diverse range of species, including Helicobacter pylori,
S. aureus, T. thermophilus, and E. coli. Percents identity range
from 26% identity for H. pylori to 41 to 42% identity for both
Thermus caldophilus and T. thermophilus (see Table S1 in the
supplemental material). In spite of moderate percent identity,
the RMSDs for these structures range from 1.5 Å2 for S. aureus
to 2.4 Å2 for H. pylori; clearly, the M. tuberculosis structure is
most similar to the S. aureus structure (25). A superimposition
of the M. tuberculosis apo monomer with Ddl structures from
other species can be observed in Fig. S3A in the supplemental
material.
The NTD (residues 1 to 140) consists of 4 -strand regions
sandwiched between 2 -helices which are conjoined by several
loop regions. The NTD also forms the upper portion of the
ligand cavity, which makes contacts with both D-Ala molecules
in the active site. Among all three regions of Ddl, the NTD
shows the most diversity in large-scale changes, with RMSDs
of 1.8 and 1.9 Å2 compared to the levels for E. coli and S.
aureus. The M. tuberculosis NTD structure for residues 64 to 93
could not be modeled, due to disorder. The S. aureus and M.
tuberculosis structures have an insertion in this region not
found in the E. coli structure. This region in S. aureus is a loop
that joins the most solvent accessible portion of the -sheet
region to the adjoining helix. Superimposition of the S. aureus
and M. tuberculosis structures would also place the missing
residues in this region. Another difference between the struc-
tures involves the loop region corresponding to residues 118 to
123 and the loop region corresponding to residues 18 to 25. All
Ddl structures solved to date have the loop region correspond-
ing to M. tuberculosis residues 18 to 25 protruding into the
active site near the first D-Ala site. In the M. tuberculosis struc-
ture this has been partially displaced by the loop region cor-
responding to residues 118 to 123. The loop region corre-
sponding to residues 18 to 25 is positioned outwards toward
the solution, contributing to disorder in the electron density
profile (Fig. 3).
The MD (residues 141 to 232) consists of a four-stranded
antiparallel -sheet region which separates a pair of -helices
at each side. The MD flanks the nucleotide binding site, form-
FIG. 2. Overall structure of M. tuberculosis Ddl and domain definition. (A) Ribbon diagram of the Ddl monomer, with helices (H) as well as
-sheet regions (B) defined. Domains are colored blue (CTD), green (MD), and purple (NTD). (B) Transparent space-filling representation of
the Ddl dimer, with a ribbon diagram shown beneath the surface. ADP and D-Ala:D-Ala dipeptide are shown as spheres colored by atom type,
which were docked in manually, using the ligand-bound form of E. coli Ddlb (PDB accession code 1IOV) as a guide (14). Monomers are denoted
by different colors (green and purple).
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ing half of the sandwich which holds the nucleotide in place
along with the CTD. The nucleotide rests flush against the
-sheet region of the MD (see Fig. S3B and C in the supple-
mental material). The loop region corresponding to M. tuber-
culosis residues 196 to 203 is inserted into the active site,
making contact with the nucleotide phosphate region. The MD
domain shows very few global differences with other Ddl struc-
tures, with RMSDs of 1.1 and 1.2 Å2, respectively. The region
with the most striking difference in the MD is the random coil
region corresponding to residues 196 to 204, which is displaced
approximately 4.5 Å inward toward the center of the protein
away from the bulk solvent region compared to the levels for
other species.
The CTD (residues 233 to 373) is formed by a core of six
antiparallel  strands and by the  loop, which extends into the
ligand binding pocket and is known to be important in catal-
ysis. In addition, the -sheet region is capped by 3 -helices,
one of which, H10, forms the interface with the NTD. The core
of the CTD is globally well conserved among species, with M.
tuberculosis having core RMSDs of 1.6 Å2 compared to the
levels for E. coli and S. aureus. The most striking area of
divergence in the CTD in M. tuberculosis compared to the
levels for other species is localized to the  loop (Fig. 3). Prior
to our M. tuberculosis structure, apo structures were available
for the species H. pylori, S. aureus, and T. thermophilus. The M.
tuberculosis apo structure has the  loop pulled into the ATP
binding site partially overlapping this site. No other apo Ddl
structure has the  loop in this type of conformation. To
accommodate the nucleotide, this region must flex outwards
toward the solution. In contrast, structures from H. pylori and
T. thermophilus have the  loop in a conformation that forms
an antiparallel -sheet capped by a loop which extends 180
degrees in the opposite direction of the ATP binding site
directly into the bulk solvent. The apo structure from S. aureus
does not contain the  loop, as the residues were too disor-
dered in the electron density to be modeled, implying they
were highly mobile. The flexibility of this region has also been
confirmed previously for DdlA and DdlB from E. coli and the
VanA vancomycin-resistant determinant of Enterococcus fae-
cium by limited proteolysis (44). Therefore, apo M. tuberculosis
Ddl has a conformation distinct from that of other apo struc-
tures in that Ddl directly blocks the ATP binding site. In other
Ddl structures from other bacteria, the ATP binding site is in
an open conformation where the  loop is either highly mobile
or locked in a position protruding into the solvent region.
The dimer interface is disrupted by an M. tuberculosis-spe-
cific insertion. The M. tuberculosis dimer interface is almost
completely defined by contacts of the  helices between sub-
units extending from the MD domain (Fig. 4A). Three  he-
lices are predominantly involved in the dimer interface inter-
actions: H4, H5, and H3. Subunit-subunit -helical packing is
such that H3 of one monomer packs against H3 of its dimer
partner and H4 of one monomer packs against H4 of its dimer
partner; both  helices pack against their partners, with an
offset angle of approximately 180 degrees (Fig. 4A and B). In
contrast to the Ddl structures of other species which report
primarily hydrophobic interactions at the dimer interface (13,
23), M. tuberculosis Ddl includes a variety of interactions, in-
cluding hydrophobic, electrostatic, and van der Waals interac-
tions. Interactions of the dimer interface can be divided into 3
basic groups: hydrophobic and van der Waals interactions of
the H4/H5-H4/H5 interface (Fig. 4A and B), hydrophobic and
van der Waals interactions of the H3/H3 interface (Fig. 4A, B,
and C), and a variety of electrostatic interactions (Fig. 4D). H4
and H5 of one monomer pack against H4 and H5 of the dimer
partner to create a hydrophobic environment in which residues
Ala147, Leu158, Phe154, and Val143 of both monomers are all
involved in hydrophobic interactions (Fig. 4B). In addition, H3
of one monomer packs against H3 of its dimer partner, with a
hydrophobic interaction occurring between the side chains of
Leu130 of both monomers (Fig. 4C). Lastly, two electrostatic
interactions tie the monomers together as seen in Fig. 4D, the
Lys157 side chain of H5 forms an electrostatic interaction with
the side chain of Asp162 of H5 on the dimer partner, and the
side chain of Asp310 at the base of H9 forms an electrostatic
interaction with the side chain of Arg173 (Fig. 4D). Electro-
static interactions of this nature are not observed in the dimer
interfaces of Ddl molecules from other species.
A comparison of multiple Ddl sequences reveals that the M.
tuberculosis structure contains an insertion in the amino acid se-
quence not found in most other species, as indicated in the mul-
tiple sequence alignment displayed in Fig. S4 in the supplemental
material. This insertion consists of residues 95 to 107 compared to
the S. aureus sequence and residues 81 to 107 compared to the E.
coli sequence. This region forms a small helix surrounded by a coil
tertiary structure just upstream of helix 2. This coil region is
largely hydrophobic, creating steric hindrance which prevents he-
lix 2 from packing directly against helix 3 as seen in other species
(Fig. 4E). Helix 2 is found in the M. tuberculosis structure packed
FIG. 3. The Ddl active site requires conformational changes.
Shown is a superimposition of the ligand-bound form of E. coli Ddlb
(PDB accession code 1IOV) with apo M. tuberculosis Ddl. Residues
shown as sticks are residues predicted to be involved in the D-Ala:D-Ala
ligation reaction (14). Red arrows indicate structural rearrangements
that would need to occur for apo M. tuberculosis Ddl to form a ligand-
bound conformation such as the E. coli conformation depicted.
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against the -sheet cluster, allowing the coiled insertion to pack
against helix 3, forming largely hydrophobic interactions. This
alternative conformation allows helix 3 to flex nearly 5.0 Å away
from the dimer interface compared to the dimer interfaces of
other species, specifically at the helix 3-helix 3 dimer interface
interactions. The altered packing induced by the hydrophobic coil
has an impact not only on the dimer interface but on the juxta-
posed -sheet region and the loops gating the active site. The
-sheet region composed of  strands 1 to 4 is shifted as far as 2.0
Å in certain regions compared to the levels for other species.
Most intriguing, the loop region upstream of helix 3 overlaps, by
the altered dimer interface, with the D-Ala binding sites displacing
the loop bearing the catalytic Glu23.
M. tuberculosis Ddl active site. Despite exhaustive cocrystal-
lization and soaking attempts, we were unable to obtain ligand-
bound structures for ADP, ATP, or DCS. Thus, we manually
FIG. 4. Ddl dimer interface. (A) Helix packing at the dimer interface. H5, H9, and H4 all pack against their dimer partners. H4 packs against
the dimer partner H4 at an offset of almost 180o, and H5 packs against the dimer partner H5 at a similar offset. (B) Hydrophobic cleft of the dimer
interface. Residues Leu158, Phe154, Ala147, Leu144, and Val143 all form hydrophobic interactions at the dimer interface. (C) Hydrophobic
packing of H3/H3 via residue Leu130. (D) Electrostatic interactions at the dimer interface. Arg173 forms an electrostatic interaction with Asp310,
and Lys157 forms an electrostatic interaction with Asp162. (E) Superimposition of M. tuberculosis Ddl (monomer A in green ribbons and monomer
B in gray ribbons) with S. aureus Ddl (monomer A in yellow ribbons and monomer B in magenta ribbons) (PDB accession code 2I87), with the
M. tuberculosis-specific insertion shown in purple (25). The M. tuberculosis-specific insertion allows for shifts in helices 2 and 3 away from the dimer
interface compared to the levels for the S. aureus structure.
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docked ADP into the active site of our apo structure using
superimposed structures from E. coli (PDB accession no. 1iow)
and S. aureus (PDB accession no. 2i8c) (13, 25). Many, if not
most, of the residues spanning the active site are well con-
served among Ddl proteins. The purine ring is sandwiched
between Phe192 and Phe320, making stacking interactions
with both residues (see Fig. S3C in the supplemental material).
In addition, three nitrogen atoms of the purine ring participate
in hydrogen bonds: N6 is a donor to the oxygen of the side
chain of Glu230 as well as the main chain oxygen Ala231, N1
hydrogen bonds with the backbone carbonyl of Ile233, and N7
hydrogen bonds with the Lys194 side chain nitrogen (Fig.
S3C). Only one oxygen atom from the ribose sugar participates
in protein interactions; the O2 oxygen atom hydrogen bonds
with Glu237 (Fig. S3C). Both phosphate moieties are involved
in electrostatic interactions (Fig. S3C and D). The -phosphate
forms two electrostatic interactions, one with the side chain
nitrogen of Lys152 and the other with the side chain of Asn329.
The -phosphate forms only one hydrogen bond with the side
chain oxygen of Ser200.
Inspection of the binding site in comparison to the E. coli
D-Ala:D-Ala dipeptide intermediate mimic allowed us to define
the portion of the active site encompassing both D-Ala binding
sites (Fig. 3 and 5A) (14). The first D-Ala binding site, the
N-terminal site, is defined by three highly conserved residues:
His118, Gly336, and Arg316. The carbonyl group of D-Ala is
positioned to hydrogen bond with the backbone nitrogen of
Gly336 as well as the NH2 moiety of the Arg316 side chain.
The M. tuberculosis Arg residue is very well conserved, with
RMSDs over all atoms of 1.0 and 0.9 Å for S. aureus and E.
coli, respectively. The glycine residue of the D-Ala1 site is
moderately conserved, with RMSDs over all atoms of 1.5 and
2.5 for M. tuberculosis compared to the levels for S. aureus and
E. coli, respectively. All structural reports among species thus
far have identified an N-terminal glutamic acid as a key residue
of the N-terminal D-Ala site, with the side chain acting as a
hydrogen bond donor to the D-Ala amino group. Interestingly,
in the M. tuberculosis structure this residue, Glu23, is part of a
disordered loop that, based on the location of the base of each
end of the loop, we infer extends away from the globular region
of the protein. The active-site region, filled by this catalytic
glutamate residue in other species, is instead occupied by
Glu123 in the M. tuberculosis structure (Fig. 3). This is made
possible by the complete repositioning of this region of the
FIG. 5. M. tuberculosis apo Ddl active-site cavity and adjoining clefts. Apo Ddl is shown as a surface representation (purple). Manually docked
ADP (colored yellow by atom) and D-Ala:D-Ala (red) are shown as stick representations, using the ligand-bound form of E. coli Ddlb (PDB
accession code 1IOV) as a guide (14). The  loop was removed from all representations to allow for a clear view of the binding pocket.
(A) Overview of the apo M. tuberculosis Ddl pocket. (B) A cleft behind the D-Ala binding site extends back and away from the binding pocket.
(C) A shallow cleft lies to the right of the ATP sugar group oxygen atoms. (D) A deep cleft lies below the nucleotide binding site.
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active site compared to homologous structures. The loop re-
gion between B4 and H3 fills this side of the active site, allow-
ing Glu123 to be positioned next to D-Ala, whereas in homol-
ogous structures, this side of the active site is formed by the
loop adjoining H2 and B1. In addition, the conserved histidine
(His118), shown to pack against the first D-Ala molecule in
other species, is also found on a loop that would require sig-
nificant remodeling to pack against the D-Ala1 site (Fig. 3). The
second C-terminal D-Ala2 site is also defined by highly con-
served residues among species and includes residues Tyr277,
Ser341, and Met342. The apo structure shows that the end of
H10 and the beginning of H11, bearing the  loop and con-
served Tyr277, require a shift away from the ligand cavity of
approximately 5 to 7 Å to make contact with D-Ala2 (Fig. 3).
This outward shift also allows for the ATP site to open and be
freed from the occupying Ddl residues. Upon the helix shift,
the hydroxyl group of Tyr277 is in place to be a hydrogen bond
acceptor to the D-Ala amino group. While this residue is absent
due to disorder in the S. aureus structure, the E. coli structure
has an RMSD of 6.2 Å2 compared to the level for the M.
tuberculosis structure. In addition, H10 is positioned such that
the Ser341 hydroxyl and Met342 main chain nitrogen both
require a small shift to be in position to hydrogen bond with
the D-Ala carboxyl group (Fig. 3).
M. tuberculosis-specific active-site clefts. Three clefts
branching from the active site of apo M. tuberculosis Ddl are
not present in other species or are present with larger and
more-encompassing volumes. The first cleft is located proxi-
mally to the D-Ala binding site, making the design of inhibitors
which span from the first D-Ala site as well as into this cleft an
attractive possibility (Fig. 5B). The cleft is homologous to a
cleft previously reported for the S. aureus structures but absent
in all other species to date. This cleft in M. tuberculosis is
deeper than the homologous S. aureus cleft extending directly
back from the D-Ala binding site nearly 13 Å in length. The
opening of the cleft is nearly 7 Å wide and is defined by
residues His118, Ser30, Ser341, and Met334. While the open-
ing of the S. aureus cleft shares conserved residues on a pri-
mary sequence level and Ser30, Ser341, and Met334 show little
variation between the two species spatially, the loop bearing
His128 is shifted approximately 6 Å away from the active site
in M. tuberculosis compared to the level for S. aureus. This shift
in M. tuberculosis compared to the level for S. aureus directly
away from the active site not only creates a different environ-
ment at the cleft opening but also creates a unique environ-
ment along the wall of the cleft. The second cleft of interest,
found on the M. tuberculosis active site, is unique to M. tuber-
culosis compared to other structures (Fig. 5C). The cleft is
relatively shallow, 3.5 Å deep, and the opening is formed by
residues Asp318, Glu239, Glu237, and Val327, which form a
5-Å-diameter opening. The location of this cleft next to the
ATP sugar ring makes this cleft the most suitable site for
rational inhibitor design. The cleft lies near the O3 oxygen
atom of the ribose ring of the ATP molecule, making it an
appealing target for ATP analogs, with moieties extending
from the oxygen atoms of the ribose sugar. While the cleft is
shallow, its location proximal to the proposed ATP site would
allow for substitution of ATP analogs quite readily, given that
the diameter and depth could accommodate a wide variety of
different chemical moieties. The last notable cleft of the M.
tuberculosis structure is located lining the opposite side of the
ATP molecule as the D-Ala sites and the previously mentioned
cleft (Fig. 5D). This cleft is also seen in most of the other Ddl
structures to date, but not as deep or wide as in the M. tuber-
culosis apo structure. The cleft opening is approximately 8 Å
wide and 12 Å long, formed by residues Asp318, Glu239,
Glu237, and Val327, and extends about 12 Å away from the
ligand binding pocket. The opening of the cleft is located close
to the proposed sites of the ATP phosphate moieties, making
this cleft an engaging target for rational inhibitor design of
moieties designed from scaffolds based on ATP analogs as well
as D-Ala:D-Ala intermediate analogs. Additionally, given that
many of the clefts are lined with charged residues, this allows
for the introduction of hydrogen bonding networks to improve
the affinity of D-Ala and ATP mimics.
DISCUSSION
The genes for D-alanine racemase and Ddl are present as a
single copy in all sequenced mycobacterial genomes (http:
//www.ncbi.nlm.nih.gov/genomes). These enzymes catalyze se-
quential steps in the D-alanine pathway of peptidoglycan bio-
synthesis (43). Both enzymes are inhibited by DCS in a
concentration-dependent manner (4, 11, 15). In M. smegmatis,
D-alanine racemase insertion mutants are viable but hypersus-
ceptible to DCS (5, 6, 18), suggesting that Alr may protect a
more fundamental lethal target of lower affinity, such as, for
example, Ddl (15, 18). Nonetheless, other studies with M.
smegmatis alr deletion mutants using different experimental
conditions did not detect viable cells in the absence of D-
alanine (29). Ddl essentiality in M. smegmatis is also substan-
tiated by genetic experiments, including one involving the iso-
lation of a mutant whose thermosensitive phenotype was
complemented to thermoresistance by supplying a wild-type
ddl gene (3). The D-alanine racemase and Ddl genes have both
been identified as essential genes in M. tuberculosis by two
methods of genome-wide analysis based on transposon mu-
tagenesis at either saturation or subsaturation levels (22, 36).
Indeed, the lethal effect of DCS on M. tuberculosis may be due
to the inhibition of both Ddl and D-alanine racemase, whose
crystal structure has been solved (24). The essentiality of Ddl
in M. tuberculosis is strengthened by the involvement of Ddl in
the second step of D-Ala:D-Ala biosynthesis. Microorganisms
such as Listeria monocytogenes possess alternative pathways for
synthesizing D-alanine without D-alanine–racemase (41). How-
ever, Ddl or a highly homologous variant of Ddl (whose pres-
ence would be easily detectable in the M. tuberculosis genome
sequence, as indicated by the high homology among D-Ala
ligases from widely divergent species [http://www.ncbi.nlm.nih
.gov/sutils/blink.cgi?modequery]) is required for the synthe-
sis of D-Ala:D-Ala or another dipeptide (e.g., D-Ala–X) that
can be used instead. Ddl function is also essential in microor-
ganisms with two Ddl enzymes, as demonstrated by the ther-
mosensitive E. coli mutant ST640, with thermosensitive and
null mutations in the corresponding ddl genes (26, 47). Thus,
there are no known alternative pathways that could bypass the
requirement for a dipeptide containing D-Ala. Nonetheless,
there are no studies that provide a formal proof of D-alanine
racemase or Ddl essentialities in M. tuberculosis, and further
studies are needed to define the lethal target(s) of DCS action.
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Association/dissociation equilibrium constants have not
been reported for Ddl of any species; however, many Km values
have (47). Our binding data are consistent with previous ki-
netic studies from other species which show both high-affinity
and low-affinity events. Here, we demonstrate by binding data
that apo Ddl has high affinity for D-Ala in the absence of
nucleotide and that the addition of nucleotide confers little
added affinity for D-Ala. Likewise, the binding assays suggest
direct binding of DCS to apo and nucleotide-bound forms of
Ddl. DCS also exhibits high- and low-affinity binding events.
The value for the low-affinity constant more closely resembles
the IC50s of the inhibitor in a kinetic assay. Furthermore, the
MIC values of DCS for M. tuberculosis are also consistent with
the IC50 for Ddl inhibition by DCS. Moreover, if a mechanism
of competitive inhibition is involved, these data indicate that
DCS has an affinity just slightly greater than that of D-Ala at
both D-Ala sites, but with a greater difference at the low-affinity
site. In this situation, it is important to underscore that IC50s
are dependent not only on the absolute affinity of the inhibitor
but also on the relative affinities of the inhibitor and the sub-
strate, the substrate concentration, and the assay system (7).
Nonetheless, our IC50 data, binding data, and previous in vivo
data seem to rule out the hypothesis that the high-affinity site
alone is sufficient for inhibition. However, the Ddl reaction is
more complex than simple competitive inhibition, as the over-
all reaction follows a ter-ter mechanism (8–10) with two sub-
strates, one with two binding sites. Thus, a full kinetic analysis,
now in progress, is needed to further substantiate these argu-
ments. Thus, the M. tuberculosis Ddl enzyme has high affinity
for both D-Ala and DCS at both sites, with a greater difference
at site 2 (acceptor) than at site 1 (donor).
The crystal structure of M. tuberculosis Ddl indicates that, in
contrast to what is observed for other species, the apo protein
exists in a closed conformation and contains many cavities
adjacent to the active site. Because many unique pockets exist
in the M. tuberculosis Ddl active site, we propose that this
allows for guided design of M. tuberculosis-specific inhibitors.
The M. tuberculosis Ddl ligand binding pocket appears to be
flexible in nature, requiring several structural rearrangements
to be in position to bind ATP and both D-Ala molecules (in-
dicated by arrows in Fig. 3). The two conformations may play
a role in the complex kinetics of the ter-ter mechanism de-
scribed above. Moreover, the M. tuberculosis Ddl structure is
markedly different from previously solved structures from
other species in that the M. tuberculosis apo form must undergo
significant rearrangement for ligand binding and catalysis.
While other species, such as S. aureus, do undergo small rear-
rangements, these rearrangements are not as profound as
those that we propose for the M. tuberculosis model, as seen in
Fig. S3B in the supplemental material and Fig. 3. The flexibility
of the ligand binding pocket of M. tuberculosis Ddl is made
possible because most of the conserved catalytic residues lie on
loop regions which cap the catalytic site. Because ATP is un-
likely to bind apo M. tuberculosis Ddl in its current conforma-
tion, due to clashing, and drawing from comparisons to ligand-
bound forms of Ddl from other species, we propose that there
are two distinct conformations of M. tuberculosis Ddl. The
more rigid and closed ligand-bound conformation will be re-
ferred to as the closed conformation, and the more flexible
conformation we shall denote the open conformation. The
transition from the closed to the open conformation requires
three distinct events: (i) the outward movement of the  loop
from the ligand binding cleft toward the solution, (ii) the dis-
placement of the loop bearing Glu123 with the loop bearing
Glu23, and (iii) an inward movement toward the active site of
the loop containing the catalytic residues, including Gly336, as
well as the loop bearing the conserved residue Ser201. The
movement of the  loop not only allows for the space required
for nucleotide binding but also places the conserved catalytic
residue Tyr277 into the D-Ala2 active site so that this residue is
capable of hydrogen bonding with D-Ala2 via the D-Ala mole-
cule’s amino group. The displacement of the loop bearing
Glu123 with that bearing Glu23 is an event that places the
conserved Glu23 and His118 residues from their position dis-
tant from the active site to a position at the D-Ala1 site, allow-
ing Glu23 to hydrogen bond with the amino group of D-Ala1.
The movement of the loop containing Ser201 inward would
allow for a hydrogen bond with Glu23 of approximately 2.8 Å,
as seen in Ddl structures from other species, and van der Waals
packing of the Tyr277side chain nearly 4 Å from the Ser side
chain, allowing for a more rigid conformation. Finally, in the
open conformation, Tyr277 is positioned such that it forces the
loop containing the conserved catalytic residues Met342,
Ser341, and Gly336 in an outward position; once the  loop is
positioned more outwardly, Tyr277 is repositioned, and the
loop containing Gly336, Ser341, and Met342 move inward to-
ward the D-Ala binding sites, allowing for catalysis.
In summary, known Ddl inhibitors, such as DCS, directly
compete with one or both of the D-Ala binding sites or are
allosteric inhibitors which overlap with the D-Ala active sites.
Because in the M. tuberculosis Ddl structure the M. tuberculo-
sis-specific cavities overlap with the active site, we propose that
this allows for the design of specific inhibitors, but additional
modeling and experimentation are needed to determine the
suitability of these sites for targeting. Nonetheless, we predict
that specific Ddl inhibitors, especially the allosteric kind, will
be bactericidal agents in their own right that could be com-
bined with specific inhibitors of other essential functions of M.
tuberculosis. In summary, the crystal structure of the M. tuber-
culosis Ddl enzyme and the kinetic and binding studies pre-
sented can be used as a guide for targeting new inhibitors by
rational drug design.
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